Pegylated arginine deiminase: a novel anticancer enzyme agent. - Wikidata - wikimedia - TriplyDB

Pegylated arginine deiminase: a novel anticancer enzyme agent.

Pegylated arginine deiminase: a novel anticancer enzyme agent.

http://www.wikidata.org/entity/Q34911774

about

The metabolic advantage of tumor cells Arginine deprivation therapy for malignant melanoma Arginine Metabolism in Bacterial Pathogenesis and Cancer Therapy Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma Emerging PEGylated drugs.Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts.Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events.Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin Recombinant human arginase toxicity in mice is reduced by citrulline supplementation Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.Mesothelioma: a review.Modeling cancer metabolism on a genome scale.Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.Gas6/Axl is the sensor of arginine-auxotrophic response in targeted chemotherapy with arginine-depleting agents.BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma.TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation.Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma.Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.Cancer cell metabolism: one hallmark, many faces.Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.Drug-induced amino acid deprivation as strategy for cancer therapy.Arginine deiminase: recent advances in discovery, crystal structure, and protein engineering for improved properties as an anti-tumor drug.Arginine dependence of tumor cells: targeting a chink in cancer's armor.Purification, immobilization, and biochemical characterization of l-arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: anticancer activity in vitro.A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia.Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4.Arginine deiminase originating from Lactococcus lactis ssp. lactis American Type Culture Collection (ATCC) 7962 induces G1-phase cell-cycle arrest and apoptosis in SNU-1 stomach adenocarcinoma cells.The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma.Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways.PEGylated arginine deiminase can modulate tumor immune microenvironment by affecting immune checkpoint expression, decreasing regulatory T cell accumulation and inducing tumor T cell infiltration.Gas6/Axl in arginine-starvation therapy.Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylated Arginine Deiminase.Purification and immobilization of L-arginase from thermotolerant Penicillium chrysogenum KJ185377.1; with unique kinetic properties as thermostable anticancer enzyme.High-throughput metabolic profiling based on small amount of hepatic cells.p53 and metabolism: from mechanism to therapeutics.

P2860

Q21245765-2E583FF2-8D07-40C8-820C-FE7628A6CA12 Q24634269-21C88A14-0D10-41C0-8FCA-D291F551CEB7 Q26765461-1CAA646B-5057-416F-9F25-369ED1B81526 Q28283880-A375A8B8-9CCB-407D-9FAC-38222EE5609D Q33447691-5E812683-2A03-4D2E-8121-CC0D7ACBA4D7 Q33630104-140E8689-7ADF-4625-BD21-0AAFB13BDE5E Q34213639-99C00906-BF01-4E8E-B00C-4BAA02F0A207 Q35170154-80554CC5-3CB4-4307-8C38-A4B5AA63AC6C Q35233239-B806F71F-0C1A-4EA7-A145-6F795578CBB1 Q35682009-9E7DEC61-CD20-4BAF-BD4E-C5ED3B4CA03B Q35742521-D4260EF1-18A8-415C-88F8-A523628C4779 Q35762225-17A0CA04-0888-473A-8B4F-FDA42CAF2ED4 Q35803555-1F6EE77F-8EE1-4C86-AA39-C2C0BD312A4F Q35839385-A2D00804-D1F4-4964-9673-E12F71AF7A88 Q35850350-7188BAB2-BF9E-4A76-89A0-360CA5358135 Q35957293-ACCB7F12-4BF2-4BF1-B451-AD626503F5ED Q36808017-BE7C0059-4D8D-4499-BFC1-BB69775FEA06 Q37109564-A02263CB-8004-4785-A359-DFDAA8640F33 Q37167357-F3C0DECA-6360-4871-859E-87F89CDBED85 Q37688620-E30EDE4E-8031-42D2-9A38-A1420FEA8775 Q37696195-E4DC589D-136C-4A94-AADC-9CE304427BAA Q37748811-1CED8829-668C-4800-B733-78558B52006B Q37820202-1E3FFB95-7B28-44C5-A881-1CA72BCC202A Q38046274-A043EAB4-7239-4278-8B3B-6707A9F59EC0 Q38181070-0566D500-8089-46BC-B960-F0E43313C3E9 Q38657061-2EAB0354-DC0C-41BF-A84D-D79841BDF8EB Q38777479-D0E7CCA6-0FE2-4DEF-A0B9-00A19A0A3D19 Q38816145-D7A9537A-B394-4379-A44E-AFC7F6362F66 Q38920582-B6722E6B-9F03-45AE-9B8C-5B88AF3FF66C Q39156501-1B4661FD-BA60-4B6D-8251-A34F33ECFDBA Q39771401-28840CCE-6E44-49DA-9CC4-0ADF6D0D7511 Q39822200-B3C1B5A1-CD7E-4954-9752-5819BB25C95C Q40188863-289D6C29-C504-4BEA-87DE-BCCB334B3E23 Q40669532-5FFAADDB-7215-4499-8D2E-CD81A93E242A Q41708842-165F1E4E-EC4D-4286-A224-0FD104E7961B Q41960436-DD67282C-0292-40D7-B9AA-ACFF48D1E234 Q46197347-1CB0D3C5-835A-410F-8A22-7C79F25B73C8 Q46815123-059866E3-C1A8-4D17-B175-D096A35CD11C Q48149123-061A6A12-E542-4C45-9D87-CCB4B444625A Q55002919-DC8C1F30-4862-46EE-84BA-57AFC38B1CC4

P2860

Pegylated arginine deiminase: a novel anticancer enzyme agent.

http://www.wikidata.org/entity/Q34911774

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@ast

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@en

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@nl

type

label

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@ast

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@en

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@nl

prefLabel

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@ast

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@en

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@nl

P1433

Q34911774-57693474-5572-4FC0-B060-36FC5C69D28E

P1476

Q34911774-C46DE052-DFD0-4B43-B5C6-6D4FA9BC92A5

P2093

Q34911774-8F5A3AEE-706F-4E29-B20F-731AA6C19830

Q34911774-E84F4B31-03FD-4265-BF58-E0E67BB298C0

P2860

Q34911774-01BC49C3-F365-42EA-B6C6-81AC690D4156

Q34911774-097000F7-E378-45D7-8A27-8F440E175D98

Q34911774-1973668E-832C-4690-A6CD-7818E2986ADD

Q34911774-1A3B1B1C-A486-4CC6-8A04-7756D57B9193

Q34911774-1DB2BD00-ACFE-4FF0-ABC1-60250CD966BF

Q34911774-1DCDB068-7A52-4AEC-B044-2D635737B5BC

Q34911774-2115A422-FFC8-490B-B062-59DAB526D858

Q34911774-223E17F3-60C2-44EA-BAE7-9F3E9665CAE4

Q34911774-40A87539-57EC-432C-B92F-AB781BDE75BC

Q34911774-43ED8B04-48BE-4DA9-BF94-C4599F2BE9DF

P304

Q34911774-C14C2E54-764B-49D4-87B2-6438B0599AA3

P31

Q34911774-A05D9A94-51E2-42E0-ACAD-AFEFC48C009F

P356

Q34911774-6FD8D6E8-E4A4-4511-8769-11125B8B151E

P407

Q34911774-8AB295BB-5511-4BF7-BFFA-5FE7244B490A

P433

Q34911774-253BB387-1715-49C1-8556-E64128F21FEE

P478

Q34911774-DB26217A-4C80-41DF-B644-C736612D5AE6

P577

Q34911774-9775726B-6B24-40E5-ACFE-428A617AAE81

P5875

Q34911774-45CF4519-E349-480A-8D60-F90FA9FBF7C2

P698

Q34911774-CD1ED0D1-4E3E-4D94-BA5D-E0C6F80B5623

P932

Q34911774-DD2EB2D2-09DF-4D49-AB6D-8B3003823233

P356

13543784.15.7.815

P1433

Expert Opinion on Investigational Drugs

P1476

Pegylated arginine deiminase: a novel anticancer enzyme agent.

@en

P2093

Lynn Feun

http://www.w3.org/2001/XMLSchema#string

Niramol Savaraj

http://www.w3.org/2001/XMLSchema#string

P2860

Use of ?-asparaginase in childhood ALL

Prognosis of hepatocellular carcinoma: the BCLC staging classification

Identification of differentially expressed genes in clear cell renal cell carcinoma by analysis of full-length enriched cDNA library.

Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation.

Current concepts in the management of patients with melanoma.

Controlling cancer by restricting arginine availability--arginine-catabolizing enzymes as anticancer agents.

The effects of arginine deficiency on lymphoma cells

Updated treatment approach to hepatocellular carcinoma.

Arginine deprivation and metabolomics: important aspects of intermediary metabolism in relation to the differential sensitivity of normal and tumour cells.

Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells.

P304

815-822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.15.7.815

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6997313

http://www.w3.org/2001/XMLSchema#string

P698

16787144

http://www.w3.org/2001/XMLSchema#string

P932

3086545

http://www.w3.org/2001/XMLSchema#string